Champions Oncology Q1 revenue up 8.8% to $15.2M
CSBR grew oncology revenue and margins with stronger Adjusted EBITDA, but remained loss-making and used cash in operations in the first fiscal quarter.
Rhea-AI Filing Summary
Champions Oncology, Inc. (CSBR) reported first-quarter fiscal 2027 oncology revenue of $15.2 million, up 8.8% from $14.0 million a year earlier, driven by higher core research services and increased data license revenue. Oncology services margin improved to 51% from 43%, reflecting higher revenue and lower third-party radiolabeling costs.
The company recorded a net loss of $426,000, slightly better than the $466,000 loss in the prior-year period, and generated Adjusted EBITDA of $671,000, up from $59,000, as higher gross profit offset increased investment in R&D and commercial expansion. Operating expenses rose 7.7% to $15.6 million, including higher sales and marketing and stock-based compensation.
Net cash used in operating activities was $492,000 versus $600,000 provided in the prior-year quarter. Champions ended the quarter with $4.4 million in cash and no debt, total assets of $33.3 million, and deferred revenue of $9.6 million, indicating a solid backlog of contracted work despite ongoing net losses.
Positive
- Oncology revenue grew 8.8% year over year to $15.2 million, driven by stronger core research services and higher data license revenue.
- Oncology services margin expanded to 51% from 43%, showing significantly higher direct profitability on the services business.
- Adjusted EBITDA rose to $671,000 from $59,000, highlighting improved operating leverage as revenue increased.
- Deferred revenue increased to $9.6 million, up from $8.8 million, indicating a larger backlog of contracted work.
Negative
- The company remained unprofitable, posting a net loss of $426,000 for the quarter.
- Operating cash flow was negative $492,000, a reversal from $600,000 of cash provided by operations in the prior-year quarter.
- Cash declined to $4.4 million from $4.9 million at April 30, 2026, while total liabilities increased to $28.8 million.
Filing Explained
The completed quarter showed $4,358 thousand cash and $492,000 operating cash use, alongside current and non-current operating lease liabilities.
This Form 8-K reports unaudited first-quarter fiscal 2027 results as of
The release emphasizes strong performance and materially better margins, while GAAP results still showed a net loss of
Form 8-K is the company’s report of a specified material event, so this disclosure is complete as an announcement of the quarter but not the later quarterly filing.
The filing says full details will be available on or before
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Oncology revenue: $15.2 million
Oncology services margin (Non-GAAP): 51%
Net loss: $426,000
+5 more
8 metrics
Oncology revenue
$15.2 million
Three months ended July 31, 2026, up 8.8% from $14.0 million a year earlier
Oncology services margin (Non-GAAP)
51%
Three months ended July 31, 2026; 43% in the prior-year period
Net loss
$426,000
Three months ended July 31, 2026; net loss was $466,000 a year earlier
Adjusted EBITDA (Non-GAAP)
$671,000
Three months ended July 31, 2026; $59,000 in the prior-year period
Net cash from operating activities
-$492,000
Three months ended July 31, 2026; $600,000 provided in the prior-year quarter
Cash and cash equivalents
$4.4 million
Balance at July 31, 2026; $4.9 million at April 30, 2026
Deferred revenue
$9.6 million
Balance at July 31, 2026; $8.8 million at April 30, 2026
Sales and marketing expense
$3.1 million
Three months ended July 31, 2026, up from $1.9 million in the prior-year period
Key Terms
Non-GAAP financial measures, Adjusted EBITDA, Oncology services margin, patient-derived xenograft (PDX), +1 more
5 terms
Non-GAAP financial measures financial
"This press release contains “Non-GAAP financial measures,” which are measures that either exclude or include amounts"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
Adjusted EBITDA financial
"Adjusted EBITDA increased to $671,000 from $59,000, reflecting higher revenue and improved oncology services margin"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Oncology services margin financial
"Oncology services margin improved to 51% from 43% in the prior-year period"
Oncology services margin is the percentage of revenue a business keeps after paying the direct costs of providing cancer care — such as drugs, clinical staff, infusion centers and related supplies. For investors it shows how efficiently a company turns cancer-treatment revenue into profit, similar to how a baker’s margin reflects the difference between the price of a cake and the cost of ingredients and labor; higher margins imply stronger pricing, cost control or reimbursement terms.
patient-derived xenograft (PDX) medical
"largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological"
A patient-derived xenograft (PDX) is a laboratory model created by implanting a small piece of a human tumor into an immune-compromised animal, most often a mouse, so the cancer can grow in a living system. Investors care because PDX models are used to test whether experimental drugs shrink real human tumors before expensive clinical trials, serving like a dress rehearsal that can help predict success, reduce risk, and guide which drug candidates move forward.
deferred revenue financial
"Deferred revenue | 9,552 | | | 8,828 |"
Cash a company has already received for goods or services it has promised but not yet delivered; it's recorded as a liability because the company still owes that product, service, or future revenue recognition. For investors, deferred revenue signals upcoming work or deliveries that will convert into reported sales over time and affects short-term obligations, cash flow quality, and how quickly a firm can grow recognized revenue—think of it like prepaid subscriptions or gift cards a business must honor later.
Earnings Snapshot
Oncology revenue: $15.2 million
Three months ended July 31, 2026
Oncology revenue
$15.2 million
Up 8.8% from $14.0 million in the prior-year period
Net loss
$426,000
Slight improvement from $466,000 net loss in the prior-year period
Oncology services margin (Non-GAAP)
51%
Increased from 43% in the prior-year period
Adjusted EBITDA (Non-GAAP)
$671,000
Increased from $59,000 in the prior-year period
Net cash from operating activities
-$492,000
Down from $600,000 provided by operations in the prior-year quarter
FAQ
How did CSBR’s first-quarter fiscal 2027 revenue perform year over year?
Champions Oncology (CSBR) reported oncology revenue of $15.2 million for the first quarter of fiscal 2027, an 8.8% increase from $14.0 million in the prior-year period, driven by higher core research services and increased data license revenue.
Was Champions Oncology (CSBR) profitable in the quarter ended July 31, 2026?
No. Champions Oncology reported a net loss of $426,000 for the quarter ended July 31, 2026, compared with a net loss of $466,000 in the prior-year quarter, though Adjusted EBITDA improved to a positive $671,000.
What was CSBR’s oncology services margin in the first quarter of fiscal 2027?
Oncology services margin for Champions Oncology was 51% in the first quarter of fiscal 2027, up from 43% in the prior-year period, reflecting higher revenue and lower third-party radiolabeling costs.
What were Champions Oncology’s Adjusted EBITDA and Adjusted EPS for the quarter?
Champions Oncology reported Adjusted EBITDA of $671,000, up from $59,000 a year earlier, and Adjusted basic EPS of $0.05, compared with $0.01 in the prior-year quarter, excluding stock-based compensation, depreciation, amortization and other items.
How strong is CSBR’s cash position and debt level after the quarter?
Champions Oncology ended the quarter with $4.4 million in cash and no debt. Cash decreased from $4.9 million at April 30, 2026, as the company used $492,000 of cash in operating activities during the quarter.
What were the key operating expense trends for CSBR this quarter?
Total costs and operating expenses rose 7.7% to $15.6 million. Sales and marketing expense increased to $3.1 million from $1.9 million, and research and development rose to $2.3 million from $2.1 million, reflecting investments in commercial expansion and target discovery.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 10, 2026
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction | (Commission File Number) | (IRS Employer | ||||||||||||
| of Incorporation) | Identification No.) | |||||||||||||
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201 ) 808-8400
N/A
(Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Securities registered pursuant to Section 12(b) of the Exchange Act
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||||||||||||
| Common Stock, par value $0.001 per share | CSBR | The Nasdaq Stock Market LLC | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
INFORMATION TO BE INCLUDED IN THE REPORT
| Item 2.02. | Results of Operations and Financial Condition. | |||||||
On September 10, 2026, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its first quarter ended July 31, 2026. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. | |||||||
(d)Exhibits
The following exhibit is filed herewith:
Exhibit No.
| 99.1 | Press Release dated September 10, 2026 | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| CHAMPIONS ONCOLOGY, INC. | |||||||||||
| (Registrant) | |||||||||||
Date: September 10, 2026 | By: | /s/ Robert Brainin | |||||||||
| Robert Brainin | |||||||||||
| Chief Executive Officer | |||||||||||
Exhibit 99.1
NEWSOne University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104
Champions Oncology Reports Revenue of $15.2 Million
Oncology services margin improves to 51%; Adjusted EBITDA increases to $671,000
Hackensack, NJ – September 10, 2026 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2027, ended July 31, 2026.
First Quarter and Recent Highlights:
•Revenue of $15.2 million, an increase of 8.8% year over year
•Oncology services margin of 51%, compared with 43% in the prior-year period
•Adjusted EBITDA of $671,000, compared with $59,000 in the prior-year period
•Continued investment in the Company’s commercial organization, data platform and strategic growth initiatives
Robert Brainin, CEO of Champions, commented, “We delivered strong performance in the first quarter of fiscal 2027, with improved study execution and conversion in our core research services business driving higher revenue and materially better margins. We are also seeing increased commercial activity around our data offerings as we work to broaden that business across a larger customer base.”
“At the same time, we continued to invest in our commercial organization, radiopharmaceutical capabilities, data platform and target discovery initiatives. Our focus remains on building sustainable growth across the business while continuing to improve profitability.”
David Miller, CFO of Champions, added, “Revenue increased 8.8% in the first quarter, while oncology services margin improved to 51% from 43% in the prior-year period. Adjusted EBITDA increased to
Exhibit 99.1
$671,000 from $59,000 in the prior-year quarter, demonstrating the operating leverage in the business as revenue grows.
“We are continuing to build on the foundation established last year, with a focus on driving revenue growth, maintaining expense discipline and converting that growth into improved profitability.”
First Fiscal Quarter Financial Results
Total oncology revenue increased 8.8% to $15.2 million from $14.0 million in the prior-year period. Growth was driven primarily by higher core research services revenue, reflecting improved conversion of contracted work into revenue, together with increased data license revenue.
Total costs and operating expenses for the first quarter of fiscal 2027 were $15.6 million compared to $14.5 million in the prior-year period, an increase of $1.1 million or 7.7%.
For the first quarter of fiscal 2027, Champions reported a net loss of $426,000, compared with a net loss of $466,000 in the prior-year period. Adjusted EBITDA, which is defined as net loss excluding stock-based compensation, depreciation and amortization expenses, other income or expense, taxes and a loss on the disposal of lab equipment, increased to $671,000 from $59,000, reflecting higher revenue and improved oncology services margin while the Company continued to invest in its expanded commercial organization and growth initiatives. The current-quarter net loss included $766,000 of stock-based compensation and $314,000 of depreciation and amortization expense.
Cost of oncology revenue was $7.5 million, for the three months ended July 31, 2026, a decrease of $461,000, or 5.8%, compared to $8.0 million in the prior-year period. Oncology services margin improved to 51% from 43% in the prior-year period, reflecting higher revenue and lower third-party radiolabeling costs. Oncology services margin and profit are defined below in our Non-GAAP financial information discussion.
Research and development expense for the three months ended July 31, 2026 was $2.3 million, an increase of $262,000 or 12.6%, compared to $2.1 million for the three months ended July 31, 2025. The increase was primarily attributable to higher share-based compensation expense related to Corellia, our wholly owned subsidiary focused on target discovery. Sales and marketing expense for the quarter was $3.1 million, an increase of $1.2 million, or 66.6%, compared to $1.9 million in the prior year period. The increase reflected the Company’s previously discussed investment in expanding its commercial organization to support growth in both research services and data licensing. General and administrative expense for the three months ended July 31, 2026 was $2.7 million, an increase of $103,000, or 4.0%, compared to $2.6 million for the three months ended July 31, 2025.
Net cash used in operating activities was approximately $492,000 for the quarter, driven primarily by normal working capital movements, including a decrease in accounts payable and an increase in accounts receivable. The Company ended the quarter with approximately $4.4 million of cash and no debt.
Conference Call Information:
The Company will host a conference call today at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its first quarter financial results. To participate in the call, please call 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 938837, or provide the verbal reference "Champions Oncology".
Exhibit 99.1
Full details of the Company’s financial results will be available on or before September 14, 2026 in the Company’s Form 10-Q at www.championsoncology.com.
* Non-GAAP Financial Information
This press release contains “Non-GAAP financial measures,” which are measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles (“GAAP”).
A further explanation and reconciliation and/or calculation of these Non-GAAP financial measures is included below and in the financial tables in this release.
The Company believes that the Non-GAAP financial measures presented facilitate an understanding of operating performance and provide a meaningful comparison of its results between periods. The Company’s management uses Non-GAAP financial measures to, among other things, evaluate its ongoing operations in relation to historical results and for internal planning and forecasting purposes. Adjusted EBITDA and Adjusted EPS represent measures that we believe are customarily used by investors and analysts to evaluate the financial performance of companies in addition to the GAAP measures that we present. Our management also believes that these measures are useful in evaluating our core operating results. However, Adjusted EBITDA and Adjusted EPS are not measures of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income, operating income, or EPS as indicators of our operating performance or to net cash provided by operating activities as a measure of our liquidity. We believe the Company’s Adjusted EBITDA and Adjusted EPS measures provide information that is directly comparable to that provided by other peer companies in our industry, but other companies may calculate Non-GAAP financial results differently, particularly related to nonrecurring, unusual items.
Adjusted EBITDA
Adjusted EBITDA represents net income (loss) excluding the effect of stock-based compensation and depreciation and amortization and may also exclude other items not indicative of our ongoing operating performance, when defined.
Adjusted Net Income (Loss) and Adjusted Earnings Per Share (EPS)
Adjusted net income (loss) (if denoted) and adjusted EPS exclude the effect of stock-based compensation and depreciation and amortization and may also exclude other items not indicative of our ongoing operating performance, when defined.
Oncology Services Profit and Oncology Services Margin
Oncology Services Profit is a Non-GAAP measure calculated as oncology revenue less cost of oncology revenue. Cost of oncology revenue is comprised primarily of expenses for mice, laboratory supplies, compensation, and outsourced lab services. Oncology Services margin is a Non-GAAP measure calculated as oncology services profit divided by oncology revenue.
Management believes that Oncology Services Profit and Oncology Services margin are metrics which provide a clear view of direct profitability before research and development, sales and marketing, and
Exhibit 99.1
administrative expenses are factored into our results. Management monitors these metrics closely as an indicator of pricing strategy effectiveness and resource utilization. These Non-GAAP measures should not be considered in isolation or as a substitute for GAAP measures such as operating income (loss) and net income (loss). A reconciliation to the most directly comparable GAAP measure is provided in the accompanying tables.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions and innovative data platforms to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2026 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.
Champions Oncology, Inc.
(Dollars in thousands)
Reconciliation of GAAP Net Loss to Adjusted EBITDA - (Non-GAAP) (Unaudited)
| Three Months Ended July 31, | ||||||||||||||
| 2026 | 2025 | |||||||||||||
| Net income (loss) - GAAP | $ | (426) | $ | (466) | ||||||||||
| Adjustments: | ||||||||||||||
| Stock-based compensation | 766 | 208 | ||||||||||||
| Depreciation and amortization | 314 | 358 | ||||||||||||
| Loss on equipment disposal | — | 20 | ||||||||||||
| Other expense (income), net | 6 | (75) | ||||||||||||
| Provision for tax | 11 | 14 | ||||||||||||
| Adjusted EBITDA - Non-GAAP | $ | 671 | $ | 59 | ||||||||||
Reconciliation of GAAP EPS to Non-GAAP EPS (Unaudited)
| Three Months Ended July 31, | ||||||||||||||
| 2026 | 2025 | |||||||||||||
| EPS – basic, GAAP | $ | (0.03) | $ | (0.03) | ||||||||||
| Adjustments: | ||||||||||||||
| Effect of stock-based compensation on EPS | 0.06 | 0.02 | ||||||||||||
| Effect of depreciation and amortization on EPS | 0.02 | 0.03 | ||||||||||||
| Effect of loss on equipment disposal on EPS | — | 0.001 | ||||||||||||
| Effect of other expense (income), net on EPS | — | (0.01) | ||||||||||||
| Effect of provision for tax on EPS | — | 0.001 | ||||||||||||
| Adjusted EPS - basic, Non-GAAP | $ | 0.05 | $ | 0.01 | ||||||||||
Reconciliation of GAAP Loss from Operations to Oncology Services Profit and Oncology Services Margin - (Non-GAAP) (Unaudited)
| Three Months Ended July 31, | ||||||||||||||||||||
| 2026 | 2025 | |||||||||||||||||||
| Loss from operations - GAAP | $ | (409) | $ | (527) | ||||||||||||||||
| Add: | ||||||||||||||||||||
| Research and Development, Sales and Marketing, General and Administrative, and Loss on disposal of equipment | 8,107 | 6,527 | ||||||||||||||||||
| Oncology services profit - Non-GAAP | 7,698 | 6,000 | ||||||||||||||||||
| Add: Cost of oncology revenue | 7,534 | 7,995 | ||||||||||||||||||
| Oncology revenue - GAAP | $ | 15,232 | $ | 13,995 | ||||||||||||||||
| Oncology services margin - Non-GAAP | 51 | % | 43 | % | ||||||||||||||||
Unaudited Condensed Consolidated Statements of Operations (unaudited)
| Three Months Ended July 31, | ||||||||||||||||||||
| 2026 | 2025 | |||||||||||||||||||
| Oncology revenue | $ | 15,232 | $ | 13,995 | ||||||||||||||||
| Cost of oncology revenue | 7,534 | 7,995 | ||||||||||||||||||
| Research and development | 2,344 | 2,082 | ||||||||||||||||||
| Sales and marketing | 3,090 | 1,855 | ||||||||||||||||||
| General and administrative | 2,673 | 2,570 | ||||||||||||||||||
| Loss on disposal of equipment | — | 20 | ||||||||||||||||||
| Loss from operations | (409) | (527) | ||||||||||||||||||
| Other income (expense), net | (6) | 75 | ||||||||||||||||||
| Loss before provision for income taxes | (415) | (452) | ||||||||||||||||||
| Provision for income taxes | 11 | 14 | ||||||||||||||||||
| Net loss | $ | (426) | $ | (466) | ||||||||||||||||
| Net loss per common share outstanding | ||||||||||||||||||||
| basic | $ | (0.03) | $ | (0.03) | ||||||||||||||||
| Weighted average common shares outstanding | ||||||||||||||||||||
| basic | 13,897,535 | 13,788,414 | ||||||||||||||||||
Condensed Consolidated Balance Sheets
| July 31, 2026 | April 30, 2026 | ||||||||||
| (unaudited) | |||||||||||
| Cash and cash equivalents | $ | 4,358 | $ | 4,872 | |||||||
| Accounts receivable, net | 13,602 | 13,178 | |||||||||
| Other current assets | 1,332 | 1,169 | |||||||||
| Total current assets | 19,292 | 19,219 | |||||||||
| Operating lease right-of-use assets, net | 9,675 | 3,697 | |||||||||
| Property and equipment, net | 3,787 | 3,526 | |||||||||
| Other long term assets | 201 | 212 | |||||||||
| Goodwill | 335 | 335 | |||||||||
| Total assets | $ | 33,290 | $ | 26,989 | |||||||
| Accounts payable and accrued liabilities | $ | 8,308 | $ | 9,495 | |||||||
| Current portion of operating lease liabilities | 635 | 1,520 | |||||||||
| Other current liabilities | 234 | 79 | |||||||||
| Deferred revenue | 9,552 | 8,828 | |||||||||
| Total current liabilities | 18,729 | 19,922 | |||||||||
| Non-current operating lease liabilities | 9,886 | 2,992 | |||||||||
| Other Non-current Liability | 215 | 7 | |||||||||
| Total liabilities | 28,830 | 22,921 | |||||||||
| Total stockholders’ equity attributable to Champions Oncology, Inc. | 3,893 | 3,939 | |||||||||
| Non-controlling interest | 567 | 129 | |||||||||
| Total stockholders' equity | 4,460 | 4,068 | |||||||||
| Total liabilities and stockholders’ equity | $ | 33,290 | $ | 26,989 | |||||||
Unaudited Condensed Consolidated Statements of Cash Flows (unaudited)
| Three Months Ended July 31, | |||||||||||
| 2026 | 2025 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net loss | $ | (426) | $ | (466) | |||||||
| Adjustments to reconcile net loss to net cash (used in) provided by operations: | |||||||||||
| Stock-based compensation expense | 766 | 208 | |||||||||
| Operating lease right-of use assets | 268 | 310 | |||||||||
| Depreciation and amortization expense | 314 | 358 | |||||||||
| Non-cash interest | 17 | — | |||||||||
| Loss on disposal of equipment | — | 20 | |||||||||
| Allowance and estimated credit losses | (10) | (29) | |||||||||
| Changes in operating assets and liabilities | (1,421) | 199 | |||||||||
| Net cash (used in) provided by operating activities | (492) | 600 | |||||||||
| Cash flows from investing activities: | |||||||||||
| Purchases of property and equipment | (55) | (46) | |||||||||
| Net cash used in investing activities: | (55) | (46) | |||||||||
| Cash flows from financing activities: | |||||||||||
| Proceeds from the exercise of stock options | 52 | 24 | |||||||||
| Finance lease payments | (19) | (38) | |||||||||
| Net cash provided by (used in) financing activities: | 33 | (14) | |||||||||
| Net (decrease) increase in cash | (514) | 540 | |||||||||
| Cash at beginning of period | 4,872 | 9,785 | |||||||||
| Cash at the end of period | $ | 4,358 | $ | 10,325 | |||||||